Back

Watch Compare

Liminatus Pharma, Inc.

Data quality: 83%

Also listed as LIMNW Nasdaq

LIMN

Nasdaq Manufacturing Chemicals

$0.21

▲ $0.02 (11.96%)

Mkt Cap: 9.24 M

Price

$0.21

Mkt Cap

9.24 M

Day Range

$0.18 — $0.21

52-Week Range

$0.16 — $33.66

Volume

2,463,237

Open $0.18

50D / 200D Avg

$0.45

54.32% below

50D / 200D Avg

$2.58

92.01% below

Quick Summary

Key Takeaways

Negative free cash flow of -9.98 M

Growth

Revenue Growth (5Y)

N/A

Revenue (1Y)N/A

Earnings (1Y)N/A

FCF Growth (3Y)N/A

Quality

Return on Equity

N/A

ROICN/A

Net MarginN/A

Op. MarginN/A

Safety

Debt / Equity

N/A

Current Ratio0.42

Interest Coverage-13.75

Valuation

PE (TTM)

-0.91

Above sector avg (-1.98)

P/B RatioN/A

EV/EBITDAN/A

Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (44 peers)

Metric	Stock	Sector Median
P/E	-0.9	-2.0
P/B	—	5.1
ROE %	—	-51.0
Net Margin %	—	-150.2
Rev Growth 5Y %	—	9.3
D/E	—	0.3

All Fundamental Metrics

Growth
Revenue Growth (1Y)	N/A	Revenue Growth (3Y)	N/A
Earnings Growth (1Y)	N/A	Earnings Growth (3Y)	N/A
Revenue Growth (5Y)	N/A	Earnings Growth (5Y)	N/A
Profitability
Revenue (TTM)	N/A	Net Income (TTM)	-10.21 M
ROE	N/A	ROA	-627.86%
Gross Margin	N/A	Operating Margin	N/A
Net Margin	N/A	Free Cash Flow (TTM)	-9.98 M
ROIC	N/A	FCF Growth (3Y)	N/A
Safety
Debt / Equity	N/A	Current Ratio	0.42
Interest Coverage	-13.75	Asset Turnover	N/A
Working Capital	-1.66 M	Tangible Book Value	-1.65 M
Dividends
Dividend Yield	N/A	Payout Ratio	N/A
Dividend Growth (3Y)	N/A	Dividend Growth (5Y)	N/A
Consecutive Div Years	N/A
Valuation
P/E Ratio	-0.91	Forward P/E	N/A
P/B Ratio	N/A	P/S Ratio	N/A
PEG Ratio	N/A	Forward PEG	N/A
EV/EBITDA	N/A	Fwd EV/EBITDA	N/A
Forward P/S	N/A	Fwd Earnings Yield	N/A
FCF Yield	-107.91%
Market Cap	9.24 M	Enterprise Value	10.69 M
Per Share
EPS (Diluted TTM)	-0.43	Revenue / Share	N/A
FCF / Share	-0.22	OCF / Share	-0.22
EPS CAGR (1Y)	N/A	EPS CAGR (5Y)	N/A
EPS CAGR (10Y)	N/A
Efficiency
CapEx / Revenue	N/A	FCF Conversion	97.75%
SBC-Adj. FCF	N/A	Growth Momentum	N/A

Income Statement

Annual, most recent first

Metric	FY2025
Revenue	—
Net Income	-10.21 M
EPS (Diluted)	-0.43
Gross Profit	—
Operating Income	-2.97 M
EBITDA	—
R&D Expenses	2.69 M
SG&A Expenses	—
D&A	—
Interest Expense	215,903.0
Income Tax	—

Balance Sheet

Annual, most recent first

Metric	FY2025
Total Assets	512,795.0
Total Liabilities	10.33 M
Shareholders' Equity	-9.81 M
Total Debt	1.44 M
Cash & Equivalents	—
Current Assets	500,574.0
Current Liabilities	10.30 M